Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Do not call
En
Dr. Reddy's Laboratories Ltd. Share Price
Day's Range
Low
₹1,371.90
High
₹1,389.80
Price Summary
| Previous Close | ₹1,386.60 |
|---|---|
| Day's Range | ₹1,371.90 - ₹1,389.80 |
| Open | ₹1,377.00 |
| 52 Week Range | ₹1,101.00 - ₹1,414.90 |
| Volume | 12,22,604 |
| Market Cap | ₹0.12 |
| Previous Close | ₹1,386.00 |
|---|---|
| Day's Range | ₹1,372.20 - ₹1,387.00 |
| Open | ₹1,381.35 |
| 52 Week Range | ₹1,080.05 - ₹1,414.40 |
| Volume | 24,358 |
| Market Cap | ₹0.12 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 16,872.73 |
|---|---|
| Market Cap (₹ in Mn) | 0.12 |
| Dividend Yield(%) | 0.58 |
| Price/Earning (TTM) | 41.35 |
| TTM EPS (₹) | 33.52 |
| P/E Ratio | 24.97 |
| Book Value(₹) | 2.98 |
| PAT Margin (%) | 12.34 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 13.75 |
| Trade Value ( ₹ in Lacs) | 336.38 |
|---|---|
| Market Cap (₹ in Mn) | 0.12 |
| Dividend Yield(%) | 0.58 |
| Price/Earning (TTM) | 41.35 |
| TTM EPS (₹) | 33.52 |
| P/E Ratio | 24.97 |
| Book Value(₹) | 2.98 |
| PAT Margin (%) | 12.34 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 13.75 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 46186.0 | 326439.0 |
| Expenses | N/A | N/A |
| PBT | 5163.0 | 76795.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 3873.0 | 57252.0 |
About Dr. Reddy's Laboratories Ltd.
| Founded | 1984 |
|---|---|
| Managing Director | GV Prasad |
| NSE Symbol | DRREDDY |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,52,706.52 | 1,886.80 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 3,03,961.52 | 11,450.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,79,493.69 | 4,718.95 | 3,672.30 - 3,672.30 |
| Laurus Labs Ltd. | 1,29,410.18 | 2,395.10 | 917.95 - 917.95 |
| Lenskart Solutions Ltd. | 1,26,515.86 | 727.20 | 0.00 - 0.00 |
| Apollo Hospitals Enterprise Ltd. | 1,22,382.31 | 8,511.50 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,20,249.09 | 1,205.50 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,15,768.64 | 1,386.00 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,13,912.22 | 1,410.00 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,08,837.38 | 2,635.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Dr. Reddy’s Laboratories informs about press release
Dr Reddys Laboratories informs about newspaper publication
Himalaya Nutravedics India informs about monitoring agency report
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Himalaya Nutravedics India has submitted the Monitoring Agency Report, issued by Brickwork Ratings India, Monitoring Agency, for the quarter ended on September 30, 2026 in respect of utilization of proceeds of the Initial Public Offer of the Company. The above information will also be made available on the website of the Company https://himalayanutravedics.com.
The above information is a part of company’s filings submitted to BSE.
Himalaya Nutravedics India informs about statement of deviation or variation
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Himalaya Nutravedics India has informed that it attached the Statement of Deviation(s) or Variation(s) for the half year ended 30t September, 2026, duly reviewed and approved by the Audit Committee and Board of Directors of the Company at its meeting held on 12th November, 2026. The company has informed that there has been no any deviation(s) or Variation(s) in the use of proceeds as stated in the objects of the Equity issue in the offer document/ prospectus.
The above information is a part of company’s filings submitted to BSE.
Alkem Laboratories informs about change in management
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Dr. Reddy's Laboratories Ltd. is ₹1,386.60 as of 2026-11-12.
The market capitalisation of Dr. Reddy's Laboratories Ltd. is ₹115,768.64 as of 2026-11-12.
The 1-year return of Dr. Reddy's Laboratories Ltd. is 157.00% as of 2026-11-12.
The P/E ratio of Dr. Reddy's Laboratories Ltd. is 24.97 as of 2026-11-13.
The 52-week high and low of Dr. Reddy's Laboratories Ltd. are ₹1,414.90 and ₹1,101.00, respectively, as of 2026-11-12.
People Also Ask
Dr. Reddy's manufactures innovative immunotherapy drug (Zytorvi – PD-1 monoclonal antibody), generic pharmaceuticals (Abiraterone, Dasatinib, Imatinib for oncology; Pregabalin, Teriflunomide for specialty therapies), antibiotics (Daptomycin, Ciprofloxacin), pain management drugs. Global operations, multi-therapeutic portfolio spanning oncology, immunology, cardiology, neurology segments.
Dr. Reddy's collaborates with hospital networks for clinical trials, healthcare providers for treatment protocols, research institutions for drug development, global pharmaceutical partners for commercialisation, patient assistance programs through healthcare partnerships, and supply chain integration with dispensary networks ensuring drug accessibility nationwide.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
